Mandate

Vinge has acted as advisor to APG Asset Management in their investment in Areim Fund II

October 10, 2012

Vinge has acted as advisor to APG Asset Management in their investment in Areim Fund II, a real estate fund mainly focusing on office properties in larger Swedish cities. Areim Fund II has a target of commitments of SEK 2.5 billion upon final closing, which would give Areim Fund II around SEK 6-7 billion to invest.

APG has EUR 314 billion in assets under management (approximately 30% of the collective pension schemes in the Netherlands).

Vinge has about 50 lawyers focusing on private equity, of which approximately 12 are active within fund establishment (with competence within tax, corporate, M&A and finance law). Vinge has for several years been active in fund establishment and was e.g. the advisor to the first fund established in the form of a limited liability company in Sweden. Vinge has since then been involved in the majority of fund establishments in this form.

Partner in charge was Christina Kokko assisted by project manager Johan Steen and associate Jonatan Lund Kirkhoff.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025